Objectives: Limited data exist as to the reasons patients have for deciding among potentially curative treatment choices in clinically localized prostate cancer. Therefore, we carried out a descriptive pilot study to determine such motivations, sources of information, and other variables that influence how such patients choose between radical prostatectomy (RP) and brachytherapy (BT).
Methods: Three hundred fifty-one men with clinically localized Stage T1c-T3 adenocarcinoma of the prostate were treated by RP or palladium-103 BT, either alone (BTM) or in combination with external radiotherapy (BTC).